Studies don't support use of triweekly degludec

07/12/2013 | Medscape (free registration)

Type 2 diabetes patients who received triweekly degludec dosing had inferior glycemic control and a higher risk of hypoglycemia within the first 24 hours compared with those who were on once-daily glargine, two late-stage trials indicated. Evidence does not support the use of a three-times-a-week dosing of insulin degludec, researchers concluded. The findings were published in the Lancet Diabetes-Endocrinology.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA